Fluicell AB (FRA:5J90) Operating Margin %: 54.06% (As of Mar. 2026)


FRA:5J90 Fluicell AB FRA:5J90
57 GF Score
Price €2.55
GF Value €2.92
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Fluicell AB Operating Margin %?

Fluicell AB FRA:5J90 -11.15% 57 Operating Margin % is 54.06% as of Mar. 2026. GuruFocus rates FRA:5J90 with a GF Score™ of 57/100 and a GF Value™ of €2.92 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 944 Biotechnology companies, Fluicell AB ranks better than 63.14% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Fluicell AB's Operating Income for the three months ended in Mar. 2026 was €0.31 Mil. Fluicell AB's Revenue for the three months ended in Mar. 2026 was €0.57 Mil. Therefore, Fluicell AB's Operating Margin % for the quarter that ended in Mar. 2026 was 54.06%.

Good Sign:

Fluicell AB operating margin is expanding. Margin expansion is usually a good sign.

The historical rank and industry rank for Fluicell AB's Operating Margin % or its related term are showing as below:

FRA:5J90' s Operating Margin % Range Over the Past 10 Years
Min: -1205.38   Med: -728.88   Max: -20.73
Current: -20.73


FRA:5J90's Operating Margin % is ranked better than
63.14% of 944 companies
in the Biotechnology industry
Industry Median: -86.83 vs FRA:5J90: -20.73

Fluicell AB's 5-Year Average Operating Margin % Growth Rate was 12.30% per year.

Fluicell AB's Operating Income for the three months ended in Mar. 2026 was €0.31 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.22 Mil.


Fluicell AB  (FRA:5J90) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Fluicell AB Operating Margin % Related Terms


Fluicell AB Operating Margin % Historical Data

* Premium members only.

The historical data trend for Fluicell AB's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fluicell AB Operating Margin % Chart

Fluicell AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -834.78 -667.57 -806.38 -850.00 -139.67

Fluicell AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,147.62 -400.00 -230.36 -2.56 54.06

FRA:5J90 vs VRTX, REGN, ALNY: Operating Margin % Comparison

For the Biotechnology subindustry, Fluicell AB's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fluicell AB Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fluicell AB's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Fluicell AB's Operating Margin % falls into.


FRA:5J90
57GF Score
Fluicell AB FRA:5J90
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fluicell AB Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Fluicell AB's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-0.771 / 0.552
=-139.67 %

Fluicell AB's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=0.306 / 0.566
=54.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 54.06% mean?
Fluicell AB (FRA:5J90) has a Operating Margin % of 54.06% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Fluicell AB and its competitors. According to the industry distribution chart, Fluicell AB ranks #348 out of 944 companies in the Biotechnology industry, placing it in the top 36.9%.
Is Fluicell AB's Operating Margin % too high?
Fluicell AB's current Operating Margin % is 54.06%. Based on the distribution chart, Fluicell AB ranks #348 out of 944 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Fluicell AB has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fluicell AB's Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Fluicell AB ranks #348 out of 944 companies for Operating Margin %. This puts Fluicell AB in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Fluicell AB and its competitors. Fluicell AB's current Operating Margin % is 54.06%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fluicell AB stock overvalued right now?
Based on GuruFocus' analysis, Fluicell AB (FRA:5J90) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.92, compared to a current price of €2.55 — trading 12.7% below its estimated fair value. The current Operating Margin % is 54.06%. Fluicell AB's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Fluicell AB (FRA:5J90), the current Operating Margin % is 54.06% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fluicell AB (FRA:5J90) Overvalued in 2026?

Based on GuruFocus' analysis, Fluicell AB stock appears to be undervalued. The current stock price of €2.55 is trading 12.7% below its estimated GF Value™ of €2.92. GuruFocus considers Fluicell AB to be Modestly Undervalued.

Key valuation signals for FRA:5J90:

  • Operating Margin %: 54.06%
  • GF Value™: €2.92 vs. price of €2.55 (12.7% below fair value)
  • GF Score™: 57/100 with 4 warning signs

No single metric tells the full story. See the FRA:5J90 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Fluicell AB Business Description

Other Exchanges FLUI:Sweden
Address Flojelbergsgatan 8C, Molndal, Gothenburg, SWE, 431 37
Fluicell AB is a Swedish life science company that conducts development in regenerative medicine and human tissue-based screening models for drug development, with a particular focus on the areas of type 1 diabetes, cardiac safety screening models, and kidney diseases. The company's platform for the production of human tissue that is based on Fluicell's technology for high-resolution 3D bioprinting, and which enables the creation of tissue-based products for use in drug development and regenerative medicine.
57GF Score

Get the complete analysis for FRA:5J90

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.55
Price
€2.92
GF Value